WC
PTLA

Wexford Capital’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Wexford Capital’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-6,600
Closed -$371K – 207
2017
Q2 		$371K Buy
+6,600
New +$264K 0.03% 124

Other funds holding PTLA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wexford Capital's PTLA Position: Q3 2017 in Review

Wexford Capital sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2017, closing a stake of 6,600 shares — an estimated $371K sold.

Wexford Capital first reported a position in PTLA in Q2 2017 and held it in 1 quarter. The position peaked at $371K in Q2 2017. 221 funds tracked by Wall St. Rank hold PTLA as of Q3 2017.

  • Wexford Capital reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Wexford Capital sold 6,600 Portola Pharmaceuticals, Inc. shares in Q3 2017, an estimated $371K.
  • Wexford Capital first reported a position in Portola Pharmaceuticals, Inc. in Q2 2017 and held it in 1 quarter.
  • Wexford Capital's Portola Pharmaceuticals, Inc. position peaked at $371K in Q2 2017.
  • 221 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2017.

Based on Wexford Capital's 13F filing for Q3 2017, filed 13 Nov 2017.